Navigation Links
AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
Date:5/16/2013

sults for a Phase 2 trial for ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from USAMRMC.  The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development.  For additional information about AcelRx's clinical programs, please visit www.acelrx.com.

Forward Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to the release and anticipated timing of additional NanoTab System clinical trial data, anticipated timing of completion of AcelRx Pharmaceuticals' current clinical trials, submission of the NDA, and the therapeutic potential of AcelRx Pharmaceuticals' product candidates.  These forward-looking statements are based on AcelRx Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties. AcelRx Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of AcelRx Pharmaceuticals' product development activities and clinical trials; its ability to obtain and maintain regulatory approvals of its product candidates; the market potential for its product candidates; and other risks detailed in the "Risk Factors" and elsewhere in AcelRx Pharmaceuticals' U.S. Securities and Exchange Commission filings, including its Quarterly Report on Form 10-Q filed with the SEC on May 8, 2013.  AcelRx Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

(Logo:  h
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AcelRx Pharmaceuticals Reports First Quarter 2013 Financial Results
2. AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013
3. AcelRx Pharmaceuticals Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical Meeting
4. Top-line Data Show AcelRx Pharmaceuticals ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
5. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results
6. AcelRx Pharmaceuticals to Hold Fourth Quarter 2012 Financial Results Conference Call and Webcast on March 12, 2013
7. AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
8. AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. AcelRx Pharmaceuticals Provides Clinical Trial Updates
10. AcelRx Appoints Adrian Adams to Board of Directors as Chairman
11. AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... 7, 2011 In an address to ... John C. Lechleiter, Ph.D., chairman, president and chief executive ... build a new level of trust between the biopharmaceutical ... can harness innovation to help meet growing health care ...
... 2011 Merit Medical Systems, Inc. (NASDAQ: MMSI ... used primarily in cardiology, radiology and endoscopy, announced today that ... quarter ended June 30, 2011, after the close of the ... will hold its investor conference call on the same day ...
Cached Medicine Technology:Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System 2Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System 3Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System 4
(Date:7/10/2014)... one of the top public health concerns in the ... classified as obese as of 2012. As health problems ... taken to Twitter to discuss the problem. , A ... professor at the Brown School at Washington University in ... in tweets to track Twitter conversations about the issue ...
(Date:7/10/2014)... Up to 70% of Parkinson,s disease (PD) ... quality of life. Some patients have disturbed sleep/wake ... asleep, while other patients may be subject to ... extreme, PD patients may exhibit REM-sleep behavior disorder ... re-enactment, even before motor symptoms appear. A review ...
(Date:7/10/2014)... 10, 2014) A research review identifying the clinical ... first step in the process of developing evidence-based guidelines ... new report published by Neurosurgery , ... Surgeons . The journal is published by Lippincott ... Wolters Kluwer Health . , Based on analysis ...
(Date:7/10/2014)... Biomedical Research Institute (IDIBELL) and the Catalan Institute of ... new therapeutic combination to combat resistant sarcomas. The clinical ... stabilize the growth of these tumors have been published ... ., Sarcomas , Sarcomas are a rare type ... It can affect from children to older ages. It ...
(Date:7/9/2014)... WASHINGTON, DC (July 10, 2014) If you think winning ... fun for kids think again: Winning along with other mental ... each of which falls into one of 11 big fun ... that winning is all important when it comes to the ... identify and quantify what goes into this elusive conceptuntil now. ...
Breaking Medicine News(10 mins):Health News:Study looks at how Twitter can be used to address specific health issues 2Health News:Sleep disturbances, common in Parkinson's disease, can be early indicator of disease onset 2Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3Health News:New therapeutic combination to slow resistant sarcomas 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3
... other organizations must intensify efforts to improve the health ... where the lion,s share of deaths occur, says Dr. ... & gynecology. Baker is the lead author on a ... the world,s leading medical experts on women and children,s ...
... study appearing in the journal PLoS ONE, ... mathematical patterns underlying the way individuals unconsciously distribute ... their environment. These patterns appear to meet ... is a scientific law and, if confirmed in ...
... study shows , WEDNESDAY, May 26 (HealthDay News) - A ... is no longer so deadly, thanks to new technologies and ... researchers report. , A study in the May 27 issue ... the effectiveness of older and newer versions of devices aimed ...
... right thing, researcher says , WEDNESDAY, May 26 (HealthDay News) ... open the door for manufacturers and restaurants to add other ... study finds. , A team from Harvard School of Public ... found little cause for alarm. , "We found that in ...
... of Medicine of the National Academies will convene a ... Illinois at Chicago to discuss the rapidly rising rates ... UIC Midwest Conference on Diabetes and Obesity will bring ... Causes, treatment, preventive measures and policy issues will be ...
... analyzing 2.5 million screening mammograms performed on nearly one ... improved over a nine-year period. Results of the study ... Radiology . "To our knowledge, this is ... in a large representative sample of women undergoing screening ...
Cached Medicine News:Health News:Study finds 'law-like' patterns in human preference behavior 2Health News:Study finds 'law-like' patterns in human preference behavior 3Health News:Progress Made Against Once-Fatal Heart Defect 2Health News:Progress Made Against Once-Fatal Heart Defect 3Health News:Healthier Fats Replacing Trans Fats, Study Finds 2Health News:Healthier Fats Replacing Trans Fats, Study Finds 3Health News:UIC to host Institute of Medicine Meeting on diabetes and obesity 2Health News:Detection of breast cancer in screening mammography has improved over time 2
Interphlex Flexible Stablization Rods offer correction of Hammer Toes with a High level of Flexibility while maintaining correct toe length and shape....
The Continuous Wave II Arthroscopy Pump provides pulse-free, continuous fluid inflow for joint distention when used in conjunction with a high flow sheath or separate inflow cannula....
True/Fix Distal Femoral Nail System...
... part in our daily lives. But degenerative ... cause severe handicaps. A decisive consideration in ... to produce a reconstructed joint function that ... possible.,The cementless RM Finger System has proven ...
Medicine Products: